Sertraline-Related Amenorrhea in an Adolescent
Amenorrhea is one of the clinical consequences of hyperprolactinemia. Although symptomatic hyperprolactinemia is among the well-described adverse reactions of antipsychotic agents, it may also be reported with the use of selective serotonin reuptake inhibitors. Hereby, we present a case of sertraline-related hyperprolactinemic amenorrhea in an adolescent. Amenorrhea occurred 2 months after starting sertraline, and menstrual cycle restored after stopping the treatment. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Levetiracetam-Related Mania-Like Symptoms: An Adolescent Case
Levetiracetam is an antiepileptic agent that is used for partial and generalized epilepsy. Although it is well tolerated in most cases, behavioral and nonbehavioral adverse effects may be observed. Among behavioral symptoms, depression, hostility, and agitation have been frequently reported. However, mania or mania-like symptoms are relatively rare, especially in children and adolescents. Hereby, we report mania-like symptoms with levetiracetam use in a 15-year-old boy. Mania-like symptoms emerged 3 weeks after starting levetiracetam and disappeared after adding risperidone to ongoing levetiracetam treatment. (Source: Clin...
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Drug-Induced Parkinsonism Manifesting as Gait Freezing in a Patient With Traumatic Brain Injury: A Case Report
Conclusions
This is a rare report of drug-induced parkinsonism manifested as freezing of gait, which showed improvement after discontinuation of the causative drugs and subsequent rehabilitation. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Gabapentin-Associated Urinary Incontinence: A Case Verified by Rechallenge
Conclusions
Only a few cases with GBP-associated urinary incontinence have been reported in the literature. To the authors' knowledge, these cases described individuals with only 1 attempt of the use of GBP. In this way, the present case was the first to describe a subject with the recurrence of urinary incontinence with the GBP rechallenge. This adverse effect, although not potentially fatal, can be very embarrassing to patients and lead to poor compliance with therapy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
An Option to Consider for Alternating Hemiplegia of Childhood: Aripiprazole
We report the medical treatment in a case of AHC in a-12-year-old male patient with convulsions. The patient did not respond to available therapies for AHC, except for aripiprazole. After the initiation of aripiprazole therapy, duration and frequency of hemiplegia episodes were decreased. Also, he is currently seizure-free with topiramate treatment for 3 months. On follow-up, a compound heterozygous ATP1A3 mutation c.868C> T (p.R290C)/c.684 + 1G> A was determined. Aripiprazole may reduce the attacks of AHC, which are resistant to other available therapies. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Chronotherapeutics: Recognizing the Importance of Timing Factors in the Treatment of Disease and Sleep Disorders
This article also reviews innovative ways in which physicians are applying time-specified drug treatment (chronopharmacology) for sleep disorders. Here, we present a systematic description of chronopharmacology as well as definitions of key terms that, we believe, will be helpful for newcomers to the field. It is hoped that greater awareness of this new perspective on pharmacology will promote its adoption by researchers and clinicians. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Review Article Source Type: research
The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism?
Drug-induced Parkinsonism (DIP) represents the second most-frequent etiology of Parkinson syndromes after neurodegenerative disorders. It has been described mainly for antipsychotics, Ca++-channel blockers, antiemetics, and gastrointestinal prokinetics. In this article, we present a clinical case series of 10 patients, retrieved within our movement disorders hospital, with DIP under intake of opipramol. Symptoms completely resolved after drug withdrawal, and associated risk factors were old age, high doses, and presence of cortical atrophy. This frequently prescribed anxiolytic drug has so far not been associated with DIP....
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain
Conclusions
Our findings suggest that duloxetine can be effective for managing CPSP. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Factors Associated With Delirium in Surgical Intensive Care Unit Patients Treated With Supplemental Melatonin: A Case-Cohort Study
Conclusions
This study describes the use of melatonin in the SICU and characterizes the patients who receive it. Further research is needed to determine the role of melatonin in deliriogenesis and to clarify its utility as a delirioprotectant for postsurgical, critical care patients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection
Conclusions
More research is necessary to understand the syndrome and the association between PDSS and long-acting olanzapine injection. Clinicians should keep in mind that PDSS may worsen compliance in an index patient and affect the course of the illness. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Treatment of Poststroke Pathologic Laughing With Duloxetine: A Case Series
Conclusions
This case series demonstrates that duloxetine could attenuate pathologic laughing exhibited by stroke patients; however, further randomized controlled studies are necessary to validate our findings. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
A Case of Schizophrenia With Catatonia Resistant to Lorazepam and Olanzapine Monotherapy But Responsive to Combination Treatment: Is It Time to Consider Using Select Second-Generation Antipsychotics Earlier in the Treatment Algorithm for This Patient Type?
Conclusion
We propose a modification to the standard treatment protocol for catatonia, especially in those patients with schizophrenia with catatonic features. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Aripiprazole-Induced Hoarseness: A Case Report
Conclusions
We present a case of a preschool boy with attention-deficit/hyperactivity disorder and oppositional defiant disorder who displayed hoarseness after aripiprazole therapy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
A Case of Buspirone Demonstrating Immediate and Sustained Benefit in a Man With Lifelong Non–Rapid-Eye-Movement Parasomnias
Conclusion
Buspirone can be considered an effective alternate treatment option for NREM parasomnias when other medications are not preferred or cannot be prescribed. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Change of Cerebral Blood Flow After a Successful Pharmacological Treatment of Phantom Bite Syndrome: A Case Report
Conclusions
This case suggests that some central nervous system dysfunction involving dopaminergic system might be related to the pathophysiology of phantom bite syndrome. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
